Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists. 30931956 2019
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE In addition, FPLD3-associated PPARγ mutations consistently cause intra- and/or intermolecular defects; colon cancer-associated PPARγ mutations on the other hand may play a role in colon cancer onset and progression, but this is not due to their effects on the most well-studied functional characteristics of PPARγ. 30595551 2019
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 AlteredExpression disease BEFREE Therefore, dihydroartemisinin inhibits colon cancer growth by inducing apoptosis and increasing the expression of PPARγ. 29472793 2018
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 AlteredExpression disease BEFREE Comparison of the transcriptome data of metastasis-competent CTC-MCC-41 cells and of HT-29 cells (derived from a primary colon cancer) highlights the differential expression of genes that regulate energy metabolism [peroxisome proliferator-activated receptor γ coactivator 1A (<i>PPARGC1A</i>), peroxisome proliferator-activated receptor γ coactivator 1B (<i>PPARGC1B</i>), fatty acid binding protein 1 (<i>FABP1</i>), aldehyde dehydrogenase 3 family member A1 (<i>ALDH3A1</i>)], DNA repair [BRCA1 interacting protein C-terminal helicase 1 (<i>BRIP1</i>), Fanconi anemia complementation group B (<i>FANCB</i>), Fanconi anemia complementation group M (<i>FANCM</i>)], and stemness [glutaminase 2 (<i>GLS2</i>), cystathionine-beta-synthase (<i>CBS</i>), and cystathionine gamma-lyase (<i>CTH</i>)]. 28007957 2017
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE Interactions between PPAR Gamma and the Canonical Wnt/Beta-Catenin Pathway in Type 2 Diabetes and Colon Cancer. 28298922 2017
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 AlteredExpression disease BEFREE We also correlated EZR and PPARγ expression in our series of CRC specimens and the expression profiling of all five proteins levels in the publicly available colon cancer genomic data from Oncomine and Cancer Genome Atlas (TCGA) colon adenocarcinoma (COAD) datasets. 27499265 2016
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 AlteredExpression disease BEFREE Transient exposure to CDDP and induction of the CDDP resistance decreased expression of peroxisome proliferator-activated receptor-γ (PPARγ) in MKN45 and colon cancer LoVo cells. 27417252 2016
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE In conclusion, SOX9, β-catenin and PPARγ expression levels are deregulated in the CRC tissue, and in colon cancer cell lines ligand-dependent PPARγ activation unevenly influences SOX9 and β-catenin expression and subcellular localization, suggesting a variable mechanistic role in colon carcinogenesis. 23583560 2013
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE To investigate the relationship between PSF and PPARγ in colon cancer, we evaluated the effects of PSF expression in DLD-1 and HT-29 colon cancer cell lines, which express low and high levels of PPARγ, respectively PSF affected the ability of PPARγ to bind, and expression of PSF siRNA significantly suppressed the proliferation of colon cancer cells. 23516550 2013
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 AlteredExpression disease BEFREE This suggests that PPARγ expression may be an important factor for cell growth regulation in colon cancer. 22771328 2012
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 GeneticVariation disease BEFREE Stratified meta-analysis indicated that PPAR-gamma 34 C>G was associated with colon cancer (OR = 0.8, 95% CI: 0.65-0.99, P = 0.04) in random-effect model, and the G allele decreased colon cancer risk. 20440859 2010
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE We investigated if the rexinoid 6-OH-11-O-hydroxyphenantrene (IIF) potentiates the antitumoral properties of PPARgamma ligands as ciglitazone and pioglitazone, on two colon cancer cell lines: HCA-7 and HCT-116. 20510503 2010
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Therapeutic disease CTD_human These results suggest that the PPARgamma agonist, troglitazone, inhibits colon cancer cell growth via inactivation of NF-kappaB by suppressing GSK-3beta activity. 20540935 2010
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 AlteredExpression disease BEFREE We observed a marked synergism between peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and X-linked inhibitor of apoptosis (XIAP) down-regulation in colon cancer. 18704457 2009
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 AlteredExpression disease BEFREE KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. 19551868 2009
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE For in vivo studies, 1,2-dimethylhydrazine dihydrochloride (DMH) was s.c. injected to induce colon cancer in PPARgamma(+/+) and PPARgamma(+/-) mice. 19458067 2009
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE Our findings suggest that PPARgamma plays a role as a physiological regulator of colonic epithelial cell turnover and consequently predisposition to the development of colon cancer in early stage. 18391483 2008
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE Finally, EPA suppressed HT-29 cell growth and this effect was significantly reversed by the addition of GW, suggesting that in part the physiological actions of EPA are the result of PPARgamma activation. 18203887 2008
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE Expression of this protein may prevent PPARgamma ligand efficiency in colon cancer treatment. 17611675 2007
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE To elucidate cdk5's role in PPARgamma ligand-induced antiproliferation of colon cancer cells, HT-29 cells were treated with ciglitazone. 16327995 2006
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 GeneticVariation disease BEFREE There was a significant interaction between the -200A>C IGFBP3 polymorphism and the Pro12Ala PPARgamma polymorphism and risk of colon cancer (p for interaction = 0.02) with individuals being at significantly lower risk if they had both the CC IGFBP3 genotype and the PA/AA PPARgamma genotype. 16489531 2006
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 AlteredExpression disease BEFREE Based on our findings, p38 MAPK and transcription factor PPARgamma can be considered as molecular targets of resveratrol in the regulation of cell proliferation and SSAT activity, respectively, in a cell culture model of colon cancer. 16849586 2006
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 Biomarker disease BEFREE 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. 16155208 2005
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 GeneticVariation disease BEFREE High lutein intake [odds ratio (OR), 0.63; 95% confidence interval (95% CI), 0.44-0.89], low refined grain intake (OR, 0.70; 95% CI, 0.53-0.94), or a high prudent diet score (OR, 0.66; 95% CI, 0.49-0.89) and PA/AA PPARgamma genotype were associated with reduced colon cancer risk. 15894676 2005
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.600 AlteredExpression disease BEFREE In addition, PPARgamma protein levels are elevated, possibly through sequestration by activated beta-catenin in colon cancer cell lines. 15665104 2005